An estimated 13,910 new cases of soft tissue sarcoma will be diagnosed across the United States in 2026. Because these malignancies often mimic common muscle strains or minor trauma, patients frequently face diagnostic delays that complicate treatment. Benjamin J. Miller, an orthopaedic surgeon and fellow of the AAOS, notes that the rarity of the disease makes it difficult to recognize, even for active patients who assume a lingering ache is merely a result of physical exertion.

This clinical urgency now aligns with new legislative momentum in Washington. On June 9, 2026, the Senate passed S.Res.765, officially designating July as National Sarcoma Awareness Month. Joel L. Mayerson, chair of the AAOS Advocacy Council, stated that the resolution signals a federal commitment to expanding treatment access and resources for those navigating the complex landscape of the disease. With over 70 distinct subtypes of sarcoma affecting connective tissues, the Academy emphasizes that successful outcomes depend on multidisciplinary care, involving orthopaedic oncologists, radiation specialists, and rehabilitation teams working in concert.